your market intelligence analyst
Search Results
Edit Save
10 results
This is the third in a series of LillyPad blog posts on the pandemic. It is intended to provide information about what Lilly is doing to contribute to the fight in Canada and worldwide. As an innovative pharmaceutical company, Lilly is invested in finding solutions in response to the threat of COVID-19. We’re proud of what we’re doing, and we’re proud of how our industry has mobilized. Lilly’s mobilization against COVID-19 goes far beyond the research we’re doing in our laboratories and with our partners. Globally, Eli Lilly and Company and the Lilly Foundation. are actively engaged with community partners to address new and complex challenges arising from the coronavirus, including the economic impact on people most vulnerable to the downtu.
This is the first in a series of LillyPad blog posts on the emerging pandemic. It is intended to provide information about what Lilly and other pharmaceutical companies are doing to contribute to the fight in Canada and worldwide. Lilly is confronting this pandemic with everything we can. We’ve redirected scientific efforts to help solve critical issues – including potential therapeutics, diagnostics and testing. We are moving at top speed to create a potential treatment. Lilly has. to co-develop antibodies for the potential treatment and prevention of COVID-19. The collaboration will leverage AbCellera's rapid pandemic response platform and Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic anti.
Today’s blog comes from Lilly Canada’s new President and General Manager, Rhonda Pacheco. This was drawn verbatim from a statement we provided to Reuters, in response to an inquiry. A Reuters journalist was asking about. , which summarizes the impact of the new. and. governing the prices of patented medicines in Canada from our industry’s perspective. These new regulations, which lower the list prices of patented medicines here, make it harder to launch new medicines in Canada in a timely fashion. At Lilly, we’ve already suspended an application for approval to sell one new medicine here, and the regulations haven’t even taken effect yet. We’re now questioning whether it’s economically viable to invest the financial and human resources require.
By Andrew Merrick, Director of Patient Access and 31-year employee of Lilly Canada. After more than 70 years at the corner of Birchmount Rd. and Danforth Ave., this fall Lilly Canada will move our offices back to downtown Toronto. We have made decades of memories in Scarborough, so it is with mixed emotions that we make this transition. It has been an honour to be a part of the community in Southwest Scarborough. We decided to move in order to be closer to our collaborators of the past and the future—to hospitals, universities, and research facilities—and to move into a purpose-built office that fits our current size while providing flexibility for us to grow. Lilly Canada was founded in 1938 as a result of the collaboration between Eli Lill.
Today’s guest blog comes from Dr. Trevin Stratton, Chief Economist at the . As Chief Economist, Dr. Stratton works with the Chamber’s policy team to advocate for public policies that will foster a strong, competitive economic environment that benefits businesses, communities, and families across Canada. As the voice of business, the represents over 200,000 employers in Canada. Over the past few months, we’ve been asking our members about their thoughts on national pharmacare. The consensus is clear: employers agree that a national pharmacare program should raise the bar for Canadians and improve health outcomes. Employers wholeheartedly believe in the distinctly Canadian value that no one in this country should lack access to the medicines
Today’s guest blog is a conversation with two volunteers at Camp Banting, which is a sleepover camp for kids with type 1 diabetes. Sarah Lawrence MD, FRCPC (AKA Dr. Sarah) is the volunteer Medical Director at Camp Banting when she’s not working as an Associate Professor and Chief of Endocrinology at the Children’s Hospital of Eastern Ontario (CHEO). Sarah Hamilton (AKA Sarah H) also volunteers at the camp when she’s not working as an Administrative Assistant in Ambulatory Diabetes Care at CHEO. About Camp Banting. Dr. Sarah: "Every camp is special, but there’s something extra special about that bond that comes through medical camp, where everybody shares something unique that brings them together.".
Today’s guest blog comes from Doreen Osti, Senior Sales Consultant, Biomedicines at Lilly Canada. I’ll never forget the day I found out I was going to India. I had applied through Lilly’s , which matches employees to volunteer opportunities across the world. I remember being so thrilled that I would be participating as a documentary photographer. For the first time, I would get the chance to marry my passions for adventure and service with my love of photography. We partnered with (PSI), a non-profit organization, to help improve health outcomes for people with diabetes in. India through treatment, communication and education. With a population of around 1.3 billion, India is one of the fastest growing countries in the world – and approximat.
Today’s blog comes from Lydia Lanman, Senior Manager, Policy and Government Relations at Eli Lilly Canada. Canadians are fortunate in that the vast majority of us have access to some form of prescription drug coverage. Unfortunately, that doesn’t mean that every Canadian can afford the medicines they need. That’s where the push for a national pharmacare plan comes in. Lilly believes a new plan should be aimed at these gaps in coverage – without undoing the successes of the system we already have in place. To determine the best path forward, we must understand the current environment related to access to drug coverage in Canada, and how this may impact individual affordability. In its simplest form, the drug coverage “gap” includes two eleme.
Today’s blog comes from Lydia Lanman, Senior Manager, Policy and Government Relations at Eli Lilly Canada. National pharmacare in Canada is the topic on the minds of many Canadians right now. But this issue is far from new — in fact, we’ve been having this debate as a nation for over 50 years. In 1964, the Hall Commission proposed a 50/50 cost sharing model between the federal and provincial governments towards the development of a prescription drug program. Since then, various governments and stakeholders have studied, discussed, and proposed models for national pharmacare. The same questions posed over 50 years ago persist today: Who should pharmacare cover? What should it cover? How should it be delivered? How should it be financed? Shou.

Information Technologies

IT Markets

Business Issues

Companies - Public

Companies - Venture Funded


Analyst Firms

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Political Entities


Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications